IL1B and heart failure: Supporting IL1βs candidacy as an immunotherapeutic target, the phase 3 CANTOS trial, which tested the IL1β inhibitor canakinumab as a treatment for heart failure, demonstrated a greater than 50% reduction of death from all cancers39.